Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
29 February 2024 - 11:30PM
Business Wire
Conference Call on Thursday, March 14, 2024 at
8:30 a.m. ET
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering
and developing novel immunological agents to treat various cancers,
today announced that the Company will release its fourth quarter
and year end 2023 financial results before the market opens on
Thursday, March 14, 2024. Agenus executives will host a conference
call and webcast at 8:30 a.m. ET that morning to discuss the
results and provide a corporate update.
Conference Call:
To access dial-in numbers, please register here. Conference ID:
73242
A live webcast and replay of the conference call will be
accessible on the company’s website at
https://investor.agenusbio.com/events-and-presentations and via
https://events.q4inc.com/attendee/678927380.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer and
infectious diseases with a comprehensive pipeline of immunological
agents. The company’s mission is to expand patient populations
benefiting from cancer immunotherapy through combination
approaches, using a broad repertoire of antibody therapeutics,
adoptive cell therapies (through MiNK Therapeutics) and adjuvants
(through SaponiQx). Agenus is headquartered in Lexington, MA. For
more information, visit www.agenusbio.com or @agenus_bio.
Information that may be important to investors will be routinely
posted on our website and social media channels.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240229561817/en/
Investors 917-362-1370
investor@agenusbio.com
Media 781-674-4784
communications@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From May 2023 to May 2024